References
- 1. N. J. Abbott, Blood-brain barrier structure and function and the challenges for CNS drug delivery, J. Inherit. Metab. Dis. 36 (2013) 437-449; DOI: 10.1007/s10545-013-9608-0.
- 2. L. A. Khawli and S. Prabhu, Drug delivery across the blood-brain barrier, Mol. Pharm. 10 (2013) 1471-1472; DOI: 10.1021/mp400170b.
- 3. A. H. Schinkel, J. J. Smith, O. van Tellingen, J. H. Beijnen, E. Wagenaar, L. van Deemter, C. A. Mol, M. A. van der Valk, E. C. Robanus-Maandag and H. P. te Riele, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs, Cell 77 (1994) 491-502; DOI: 10.1016/0092-8674(94)90212-7.
- 4. D. S. Miller, Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier, Trends Pharmacol. Sci. 31 (2010) 246-254; DOI: 10.1016/j.tips.2010.03.003.
- 5. J. Malmo, A. Sandvig, M. K. Varum and S. P. Strand, Nanoparticle mediated P-glikoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach, PLoS ONE 8 (2013) e54182; DOI: 10.1371/journal.pone.0054182.
- 6. F. J. Sharom, ABC multidrug transporters: structure, function and role in chemoresistance, Pharmacogenomics 9 (2008) 105-127; DOI: 10.2217/14622416.9.1.105.
- 7. C. J. Bachmeier, W. J. Trickler and D. W. Miller, Comparison of drug efflux transport kinetics in various blood-brain barrier models, Drug Metab. Dispos. 34 (2006) 998-1003; DOI: 10.1124/dmd. 105.006999.
- 8. S. P. C. Cole, Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future, Annu. Rev. Pharmacol. Toxicol. 54 (2014) 95-117; DOI: 10.1146/annurev-pharmtox-011613-135959.
- 9. S. A. Kliewer, The nuclear pregnane X receptor regulates xenobiotic detoxification, J. Nutr. 133 (2003) 2444S-2447S.
- 10. B. I. Sikic, Modulation of multidrug resistance: at the threshold, J. Clin. Oncol. 11 (1993) 1629-1635.
- 11. T. Eichhorn and T. Efferth, P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs, J. Ethnopharmacol. 141 (2012) 557-570; DOI: 10.1016/j.jep.2011.08.053.
- 12. O. Khantamat, W. Chaiwangyen and P. Limtrakul, Screening of flavonoids for their potential inhibitory effect on p-glycoprotein activity in human cervical carcinoma kb cells, Chiang Mai Med. Bull. 43 (2004) 45-56.
- 13. S. Zhou, L. Y. Lim and B. Chowbay, Herbal modulation of P-glycoprotein, Drug Metab. Rev. 36 (2004) 57-104.
- 14. P. Limtrakul, O. Khantamat and K. Pintha, Inhibition of P-glycoprotein function and expression by kaempferol and quercetin, J. Chemother. 17 (2005) 86-95; DOI: 10.1179/joc.2005.17.1.86.
- 15. European Pharmacopoeia, 6th ed., Vol. 2, Council of Europe, Strassbourg Cedex 2008.
- 16. T. Sugamo, K. Nakamura and H. Tamura, Effects of cytochrome P450 inducers on the gene expression of ocular xenobiotic metabolizing enzymes in rats, J. Health Sci. 55 (2009) 923-929; DOI: 10.1248/jhs.55.923.
- 17. U. Andersson, K. Grankvist, A. T. Bergenheim, P. Behnam-Motlagh, H. Hedman and R. Henriksson, Rapid induction of long-lasting drug efflux activity in brain vascular endothelial cells but not malignant glioma following irradiation, Med. Oncol. 19 (2002) 1-9.
- 18. R. Zhang, J. Jie, Y. Zhou, Z. Cao and W. Li, Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo, Am. J. Chin. Med. 37 (2009) 657-667; DOI: 10.1142/S0192415X09007144.
- 19. J. Zhang, F. Zhou, X. Wu, Y. Gu, H. Ai, Y. Zheng, Y. Li, X. Zhang, G. Hao, J. Sun, Y. Peng and G. Wang, 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions, Drug Metab. Dispos. 38 (2010) 2179-2187; DOI: 10.1124/dmd. 110.034793.
- 20. A. Kawase, A. Yamada, Y. Gamou, Ch. Tahara, F. Takeshita, K. Murata, H. Matsuda, K. Samukawa and M. Iwaki, Effects of ginsenosides on the expression of cytochrome P450s and transporters involved in cholesterol metabolism, J. Nat. Med. (2013); DOI 10.1007/s11418-013-0791-y.
- 21. M. Hennessy, D. Kelleher, J. P. Spiers, M. Barry, P. Kavanagh, D. Back, F. Mulcahy and J. Feely, St Johns wort increases expression of P-glycoprotein: implications for drug interactions, Br. J. Clin. Pharmacol. 53 (2002) 75-82; DOI: 10.1046/j.0306-5251.2001.01516.x.
- 22. C. C. Weber, S. Kressmann, G. Fricker and W. E. Muller, Modulation of P-glycoprotein function by St John’s wort extract and its major constituents, Pharmacopsychiatry 37 (2004) 292-298; DOI: 10.1055/s-2004-832686.
- 23. Ch. Garrovo, A. Rosati, F. Bartoli and G. Decorti, St John’s wort modulation and developmental expression of multidrug transporters in the rat, Phytother. Res. 20 (2006) 468-473; DOI: 10.1002/ ptr.1880.
- 24. L. Li, J. D. Stanton, A. H. Tolson, Y. Luo and H. Wang, Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways, Pharm. Res. 26 (2009) 872-882; DOI: 10.1007/s11095-008-9788-8.
- 25. G. Scambia, F. O. Ranelletti, P. B. Panici, R. De Vincenzo, G. Bonanno, G. Ferrandina, M. Piantelli, S. Bussa, C. Rumi, M. Cianfriglia and S. Mancuso, Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target, Cancer Chemoth. Pharm. 34 (1994) 459-464; DOI: 10.1371/journal.pone.0051764.
- 26. A. B. Shapiro and V. Ling, Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein, Biochem. Pharmacol. 53 (1997) 587-596; DOI: 10.1016/S0006-2952(96) 00826-X.
- 27. M. E. Morris and S. Zhang, Flavonoid-drug interactions: Effects of flavonoids on ABC transporters, Life Sci. 78 (2006) 2116-2130; DOI: 10.1016/j.lfs. 2005.12.003.